<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953509</url>
  </required_header>
  <id_info>
    <org_study_id>5F9003</org_study_id>
    <secondary_id>2016-003408-29</secondary_id>
    <nct_id>NCT02953509</nct_id>
  </id_info>
  <brief_title>Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are:&#xD;
&#xD;
        -  To investigate the safety and tolerability, and to define the recommended Phase 2 dose&#xD;
           and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in&#xD;
           combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx).&#xD;
&#xD;
        -  To evaluate the efficacy of magrolimab in combination with rituximab in participants&#xD;
           with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the&#xD;
           efficacy of magrolimab in combination with R-GemOx in aspartate aminotransferase (ASCT)&#xD;
           ineligible DLBCL participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment in participant in Phase 1b.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Adverse Events</measure>
    <time_frame>First dose date up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate as Defined by the Investigator According to the Lugano Classification for Lymphomas</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>Objective response is defined as complete response (CR) + partial response (PR) determined by Lugano classification for lymphomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Magrolimab: AUClast</measure>
    <time_frame>Before magrolimab infusion (within 12 hours) on Day 1, 8, and 15 of Cycle 1, Day 1 and 15 of Cycle 2, Day 1 of Cycles 3, 4, 5, 9, and 13 and until safety follow-up visit (30 days ± 7 days after last dose of magrolimab); Cycle length is 28 days</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Rituximab: AUClast</measure>
    <time_frame>Before rituximab infusion (within 12 hours) on Day 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycles 3 - 6; Cycle length is 28 days</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Magrolimab: AUCtau</measure>
    <time_frame>Before magrolimab infusion (within 12 hours) on Day 1, 8, and 15 of Cycle 1, Day 1 and 15 of Cycle 2, Day 1 of Cycles 3, 4, 5, 9, and 13 and until safety follow-up visit (30 days ± 7 days after last dose of magrolimab); Cycle length is 28 days</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Rituximab: AUCtau</measure>
    <time_frame>Before rituximab infusion (within 12 hours) on Day 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycles 3 - 6; Cycle length is 28 days</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Magrolimab: Cmax</measure>
    <time_frame>Before magrolimab infusion (within 12 hours) on Day 1, 8, and 15 of Cycle 1, Day 1 and 15 of Cycle 2, Day 1 of Cycles 3, 4, 5, 9, and 13 and until safety follow-up visit (30 days ± 7 days after last dose of magrolimab); Cycle length is 28 days</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Rituximab: Cmax</measure>
    <time_frame>Before rituximab infusion (within 12 hours) on Day 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycles 3 - 6; Cycle length is 28 days</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Developed Anti-Magrolimab Antibodies</measure>
    <time_frame>Day 1 of Cycle 1 to 5, Day 1 Cycle 9, 13, and until safety follow-up visit (30 days ± 7 days after last dose of magrolimab); Cycle length is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The duration of response is measured from when the first (objective) response is met (i.e., complete response or partial response) until the first date of objectively documented progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Progression free survival is measured from dose initiation until the first date of objectively documented disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall Survival is measured from dose initiation until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>First dose date up to 5 years</time_frame>
    <description>Time to Progression is measured from dose initiation until the first date of objectively documented progressive disease criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Rate of Response Defined by the Investigator According to the LYRIC Criteria for Lymphomas</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>Objective response is defined as complete response + partial response determined by Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) criteria.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Magrolimab + Rituximab, Phase 1b Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m^2. Cycle length is 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Indolent Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2. Cycle length is 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magrolimab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase</arm_group_label>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Indolent Lymphoma</arm_group_label>
    <other_name>Hu5F9-G4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13</description>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase</arm_group_label>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma</arm_group_label>
    <arm_group_label>Magrolimab + Rituximab, Phase 2 Indolent Lymphoma</arm_group_label>
    <other_name>RITUXAN®</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4</description>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase</arm_group_label>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase</arm_group_label>
    <other_name>Gemzar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4</description>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase</arm_group_label>
    <arm_group_label>Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase</arm_group_label>
    <other_name>Eloxatin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard&#xD;
             approved therapies&#xD;
&#xD;
          -  DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL)&#xD;
             expressing CD 20, relapsed or refractory to at least 2 prior lines treatment&#xD;
             containing anti-CD20 therapy&#xD;
&#xD;
          -  Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or&#xD;
             refractory to standard approved therapies&#xD;
&#xD;
          -  DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell&#xD;
             lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment&#xD;
&#xD;
          -  Adequate performance status and hematological, liver and kidney functions&#xD;
&#xD;
          -  Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Active brain metastases&#xD;
&#xD;
          -  Prior allogeneic hematopoietic cell transplantation&#xD;
&#xD;
          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents&#xD;
&#xD;
          -  Second malignancy within the last 3 years&#xD;
&#xD;
          -  Known active or chronic hepatitis B or C infection or HIV&#xD;
&#xD;
          -  Pregnancy or active breastfeeding&#xD;
&#xD;
          -  Prior chimeric antigen receptor (CAR-T) therapy&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama At Birmingham (Uab)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35924</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center/ National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Magrolimab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

